Physician profile
Margaret E Cook
NPI 1932174299
$5,070.18
in general payments reported to CMS, 2019-2025
27 companies · $982 in 2025
The $982 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $605 · 2021: $287 · 2022: $653 · 2023: $767 · 2024: $1,100 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $984.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $604.41 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $566.04 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $438.23 | 2019-2025 | Velphoro, Nxstage System One, Velphoro |
| Novartis Pharmaceuticals Corporation | $338.66 | 2024-2025 | |
| Amgen INC. | $327.89 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $278.96 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $266.84 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $186.65 | 2019-2023 | Ultomiris |
| Ani Pharmaceuticals, INC. | $169.14 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $167.37 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $138.20 | 2019-2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $132.64 | 2023-2025 | |
| Glaxosmithkline, LLC. | $82.76 | 2021-2024 | Nucala, Benlysta |
| Opko Pharmaceuticals, LLC | $82.25 | 2021-2024 | Rayaldee |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $75.49 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.54 | 2025 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $51.84 | 2024-2025 | Envarsus |
| Horizon Therapeutics Plc | $43.30 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $28.06 | 2025 | Injectafer |
| Genentech USA, INC. | $19.88 | 2020 | |
| Nxstage Medical, INC. | $18.78 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.73 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.